Prognostic Value of NME1 (NM23-H1) in Patients with Digestive System Neoplasms: A Systematic Review and Meta-Analysis

Abstract

ObjectiveThere is a heated debate on whether the prognostic value of NME1 is favorable or unfavorable. Thus, we carried out a meta-analysis to evaluate the relationship between NME1 expression and the prognosis of patients with digestive system neoplasms.MethodsWe searched PubMed, EMBASE and Web of Science for relevant articles. The pooled odd ratios (ORs) and corresponding 95%CI were calculated to evaluate the prognostic value of NME1 expression in patients with digestive system neoplasms, and the association between NME1 expression and clinicopathological factors. We also performed subgroup analyses to find out the source of heterogeneity.Results2904 patients were pooled from 28 available studies in total. Neither the incorporative OR combined by 17 studies with overall survival (OR = 0.65, 95%CI:0.41–1.03, P = 0.07) nor the pooled OR with disease-free survival (OR = 0.75, 95%CI:0.17–3.36, P = 0.71) in statistics showed any significance. Although we couldn’t find any significance in TNM stage (OR = 0.78, 95%CI:0.44–1.36, P = 0.38), elevated NME1 expression was related to well tumor differentiation (OR = 0.59, 95%CI:0.47–0.73, P<0.00001), negative N status (OR = 0.54, 95%CI:0.36–0.82, P = 0.003) and Dukes’ stage (OR = 0.43, 95%CI:0.24–0.77, P = 0.004). And in the subgroup analyses, we only find the “years” which might be the source of heterogeneity of overall survival in gastric cancer.ConclusionsThe results showed that statistically significant association was found between NME1 expression and the tumor differentiation, N status and Dukes’ stage of patients with digestive system cancers, while no significance was found in overall survival, disease-free survival and TNM stage. More and further researches should be conducted to reveal the prognostic value of NME1.

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

“…Regarding NME1, its relevance in cancer is still controversial. a meta-analysis evaluated the prognostic value of NME1 in patients with digestive system neoplasms (including patients with HCC and gallbladder cancer, but not CCA) and reported that high NME1 levels are correlated with well-differentiated tumors and with less-severe cancer stages, with no evident correlation with prognosis [53]. In agreement with the reported metastasis-suppressing role of NME1, patients with HCC presenting lower protein levels of NME1 displayed increased metastatization [54].…”

Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures

“…To better analyze the role of immunotyping in prognosis, WGCNA was performed to three modules significantly associated with LDA score and prognosis, and we screened four potential prognostic markers of UM. Whether NME1 was indicative of favorable or unfavorable prognosis still remained unclear 34 . In neuroblastoma, high expression of NME1 is associated with poor prognosis of patients 35 , but NME1 is tumor-suppressive in many human cancers, including in breast cancer, melanoma and lung cancer [36][37][38] .…”

Nuclear nonmetastatic protein 23‐H1 expression and epithelial‐mesenchymal transition in laryngeal carcinoma: A pilot investigation

“…3 Epithelial plasticity and mesenchymal conversion are often seen in cancer cells that lose epithelial markers and leave the primary tumor, becoming more mobile and more aggressive. [7][8][9] The role of NM23-H1 in head and neck carcinomas is still being investigated and debated. 6 The nonmetastatic gene 23 (NM23) is located on chromosome 17q21, which encodes for a 17 kDa protein with 152 amino acids.…”

“…NM23-H1 was the first to be identified and has been the most studied because of its negative correlation with the development, progression, and metastasis of various malignancies. [7][8][9] The role of NM23-H1 in head and neck carcinomas is still being investigated and debated. 10 In laryngeal squamous cell carcinoma, Marioni et al 11 quite recently reported that nuclear nm23-H1 levels were lower in patients with recurrent disease; and diseasefree survival (DFS) was longer in patients whose nuclear nm23-H1 levels were >2.0%.…”